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Objective: To describe a practical method for family practitioners to stage chronic obstructive 
pulmonary disease (COPD) by the use of office spirometry.
Methods: This is a review of the lessons learned from evaluations of the use of office spirometry 
in the primary care setting to identify best practices using the most recent published evalua-
tions of office spirometry and the analysis of preliminary data from a recent spirometry mass 
screening project. A mass screening study by the American Association for Respiratory Care 
and the COPD Foundation was used to identify the most effective way for general practitioners 
to implement office spirometry in order to stage COPD.
Results: A simple three-step method is described to identify people with a high pre-test 
  probability in an attempt to detect moderate to severe COPD: COPD questionnaire, measure-
ment of peak expiratory flow, and office spirometry. Clinical practice guidelines exist for office 
spirometry basics for safety, use of electronic peak flow devices, and portable spirometers.
Conclusion: Spirometry can be undertaken in primary care offices with acceptable levels of 
technical expertise. Using office spirometry, primary care physicians can diagnose the presence 
and severity of COPD. Spirometry can guide therapies for COPD and predict outcomes when 
used in general practice.
Keywords: chronic obstructive pulmonary disease, spirometry, family practice, primary care 
physician
Introduction
Spirometry is the most reproducible, standardized, and objective way of measuring 
airflow obstruction for the diagnosis and management of chronic obstructive pulmonary 
disease (COPD).1 The spirogram, first described by John Hutchinson in 1846, is the 
  oldest clinical test still in use today to measure patients’ maximum exhalations from total 
lung capacity.2 In obstructive pulmonary disease, the changes seen in spirometry are a 
reduction in forced expiratory volume in the first second (FEV1) – commonly referred 
to as “airflow” in primary practice – with respect to forced vital capacity (FVC). Using 
these measurements, the primary care physician can diagnose the presence and sever-
ity of airway obstruction3,4 and assess the risk of COPD, lung cancer, coronary artery 
  disease, and stroke.5 Spirometry can be incorporated into family practice with acceptable 
levels of technical adequacy and accurate interpretations,6 the results of which have 
been shown to influence general practitioner management of patients with previously 
diagnosed asthma and COPD.3 A recent evidence-based review project7 concluded that 
spirometry by primary care physicians should be reserved for high-risk subjects, eg, 
smokers aged .40 years with symptoms, who would benefit from in-depth evaluation Clinical Interventions in Aging 2011:6 submit your manuscript | www.dovepress.com
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and management.4,8,9 All smokers should be encouraged to 
stop smoking, regardless of whether or not they have COPD. 
Although it has been argued that office spirometry should 
not be used to encourage smokers to stop, because a normal 
spirogram in an active smoker may encourage continuation of 
the behavior and give a patient a false sense of being disease 
free,10–12 it has been demonstrated that abnormal spirometry 
and informing a patient of their “lung age” are effective 
  strategies in encouraging smoking cessation.7,13
The exact definition of COPD can be complex but 
should be considered in a patient who has dyspnea, chronic 
cough, or sputum production and/or a history of exposure 
to risk factors (eg, smoking/second-hand smoke, or biomass 
fuels) with airflow obstruction that is partially reversible 
with acute use of bronchodilators.1 Typically, patients with 
asthma respond more fully to bronchodilators than those 
with COPD, but there is no clear-cut presentation; for 
example, patients with well established COPD have been 
shown to have better responsiveness to acute use of bron-
chodilators than previously expected,14 and asthmatics may 
have very little airway dilation, especially if they have used 
their bronchodilator therapy before arriving for spirometry. 
Some asthma patients will not exhibit substantial airway 
responsiveness to bronchodilators until their therapy has 
the asthma under better control.15 Basing clinical decisions 
and plans on airway response to bronchodilators is therefore 
often controversial.
The severity of COPD should be assessed once the 
diagnosis has been made using the 2009 updated guidelines 
from the Global Initiative for Chronic Lung Disease (GOLD) 
to determine the degree of spirometric abnormality and by 
the presence of complications, such as respiratory failure 
and/or right-sided heart failure.1,16,17 The GOLD guidelines 
propose four stages of COPD based on spirometry: FEV1/
FVC ratio , 0.70 and FEV1 . 80% predicted (Stage 1 Mild), 
FEV1 of 50%–80% predicted (Stage 2 Moderate), FEV1 of 
30%–50% predicted (Stage 3 Severe), and FEV1 , 30% 
predicted or FEV1 , 50% predicted plus chronic respiratory 
failure (Stage 4 Very Severe). Patients with symptoms of 
GOLD Stage 1 COPD can have significant abnormalities of 
ventilatory mechanics with greater exertional symptoms and 
exercise limitation than age-matched healthy subjects.18
Is screening spirometry a waste  
of resources?
Spirometry should be used to stage COPD and to guide 
therapy. Diagnosing airflow obstruction is important because 
there are effective therapeutic interventions in asthma and 
COPD that improve outcomes.1,16 Staging COPD using the 
GOLD guidelines for FEV1/FVC ratio and FEV1 in general 
practice with office spirometry provides a logical framework 
to guide therapy. Examples of interventions include smoking 
cessation,19 drugs,20,21 oxygen,22 rehabilitation,23 and surgical 
options.24 Treatment goals should include improving quality 
of life and exercise tolerance and decreasing the number of 
exacerbations. If exacerbations can be reduced, then health 
care costs will be reduced by fewer hospitalizations and vis-
its to the emergency department. It is important to confirm 
that respiratory symptoms suggest COPD and are the result 
of airflow obstruction. A decision will need to be made 
regarding whether a bronchodilator via an inhaler should be 
administered to improve airflow.
The prevalence of COPD in a primary care setting in 
patients with a smoking history and self-reported bronchitis 
has been studied.25,26 A recent multicenter, cross-sectional 
study by Yawn et al determined the percentage of patients 
with airway obstruction (post-bronchodilator FEV1/FVC 
ratio # 0.70) compared with those without airway obstruction 
(post-bronchodilator FEV1/FVC ratio . 0.70) and confirmed 
26% patients with airflow obstruction consistent with COPD. 
This latter group had a mean age of 52.9 years, an FEV1 of 
81.4% predicted, a smoking history of 39.8 pack-years, and 
reported chronic bronchitis symptoms.26 Airflow obstruction 
has been observed to increase with age and smoking history, 
and Yawn et al noted that slight or moderate dyspnea was 
reported by 68% of the patients with a post-bronchodilator 
FEV1/FVC ratio # 0.70.26 The majority of the patients with 
newly diagnosed COPD had not discussed their coughing 
with their doctor and continued to smoke.26 Several studies 
around the globe have found that many patients with COPD 
remain undiagnosed in the primary care setting.8,25,26 Use of 
spirometry in patients with a smoking history and chronic 
bronchitis symptoms can aid in the diagnosis of COPD, 
allowing early treatment;8,25,26 however, screening patients at 
risk of COPD remains controversial,1 and the US Preventive 
Services Task Force (USPSTF) recommends against screen-
ing adults for COPD using spirometry following a systematic 
review of evidence of the benefits and harms and an assess-
ment of the net benefit.27 Each patient needs to be evaluated 
individually, according to their smoking history, lifestyle, and 
  comorbidities, prior to a decision to perform spirometry.
Lessons learned from mass 
screening experience
The lessons learned from mass screening of people out-
side of primary care offices have led to the   following Clinical Interventions in Aging 2011:6 submit your manuscript | www.dovepress.com
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  recommendations by the American Association for 
  Respiratory Care (AARC) and the COPD Foundation:28
1.  Use a COPD questionnaire to identify those at risk.
2.  Use an electronic device to detect those likely to have 
a low peak flow.
3.  Only perform spirometry on those at higher risk of COPD 
(smoking, biomass fuel exposure).
4.  Take the time to perform good spirometry.
The AARC, the COPD Foundation, and Columbia 
  University have completed a pilot study,29 which screened 
4901 people for COPD using a shortened version of the 
  Martinez et al population screening questionnaire,30 peak 
expiratory flow measurement (PEF), and spirometry. The 
study used a three-step method (Figure 1)29 to identify 
people with a high pre-test probability in an attempt to detect 
  moderate to severe COPD.28,29
Spirometry basics
Spirometry is the gold standard for the diagnosis and assess-
ment of COPD, as it is the most reproducible, standardized, 
and objective way of measuring airflow obstruction.1 It also 
detects airway obstruction in people with poorly controlled 
asthma. If PEF is ,70% predicted, simple spirometry should 
be performed on a portable spirometer.
Spirometry can be undertaken in primary care offices 
with acceptable levels of technical adequacy and   accurate 
  interpretations, and can alter clinical decisions in the 
  management of asthma and COPD.6,31 In April 2010, the 
Office Spirometry Certificate (OSC) was presented to 
the AARC state representatives meetings; it was presented 
again at the American Thoracic Association meeting (ATS) 
in May 2010. The OSC is a national initiative whose aim is to 
“teach practitioners to obtain good quality spirometry .90% 
of the time, standardize testing performed in the office 
  setting, assure test accuracy and validity and to ensure 
staff   competency” (http://www.aarc.org/osc/). The process 
consists of an Internet-based online exam and additional 
direct competency-based testing, and is intended to provide 
a way for people outside the traditional pulmonary function 
laboratory setting to demonstrate understanding and receive 
quality feedback on performance. Having two trained and 
certified spirometer experts as part of a practice team is the 
ideal situation in which to provide the most readily available 
and reliable spirometry.
The National Lung Health Education Program (NLHEP) 
has recommended that all smokers aged 45 years and 
older have a screening lung function measured by simple 
spirometry;32 however, PEF is quicker to measure than 
spirometry,33 although this would require two devices and 
would not be supported by all health authorities. Older 
patients often have multiple chronic health problems that 
can magnify the impact of COPD on a patient’s health status 
Step 1: COPD Questionnaire
Step 2: PEF
Step 3: Spirometry
6. Have you ever smoked (more than 100 cigarettes in lifetime)? If yes, have
    you smoked in last 6 months?
5. Have you been exposed to second-hand smoke, chemicals, fumes, and dust
    or air pollutants?
4. Over the last year has your breathing kept you from doing as much as you
    used to?
3. Has a doctor ever said you have asthma?
2. Do you cough up “stuff” (mucus or phlegm) almost every day?
1. Have you had a wheezing, whistling, or squeaking sound in your chest in the
    past 12 months?
•   If no positive answers - do not continue to step 2.
•   Age >40 years: one or more positive answers – move to step 2.
•   Age <40 years: two or more positive answers – move to step 2.
•   6 questions used to detect COPD risk factors, eg, wheeze, asthma, mucus,
    dyspnea, irritants, and tobacco use.
• Measurement of PEF using an electronic pocket device is done easily and quickly.
  Use of inexpensive, disposable, one-way mouthpieces with the electronic peak flow
  minimizes cross-contamination.
• PEF or FEV1 <70% predicted, – move to step 3.
• PEF > Predicted level or FEV1 > 70% Predicted – do not continue to step 3.
• Simple spirometry performed using a portable spirometer.
Figure 1 Three-step method to identify people with a high pre-test probability for moderate to severe COPD.29
Abbreviations: COPD, chronic obstructive pulmonary disease; Fev1, forced expiratory volume in the first second; PEF, peak expiratory flow measurement.Clinical Interventions in Aging 2011:6 submit your manuscript | www.dovepress.com
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and can   complicate the management of COPD.   Confirming 
the diagnosis of COPD is an important first step. The preva-
lence of airway obstruction in the US increases in smokers 
aged .40 years and reaches a peak of 31% in all men aged 
65–75 years who are currently smoking.34 In 2004, the NLHEP 
implemented a spirometer review process to encourage the 
development of simple office-based spirometers for use in the 
primary care setting.35 The goal of this process is to clarify the 
elements required to make a device appropriate for use in the 
primary care physician’s office and to provide a checklist of 
these elements for use by companies and reviewers to validate 
the device. As of January 2010, the NLHEP has approved 
four outpatient spirometers, which are reliable, accurate, and 
affordable; these are listed on the NLHEP website with links 
to the manufacturers of the   devices.35 They comprise the NDD 
EasyOne Frontline 2000–2, the EasyOne Diagnostic 2001–2 
(www.nddmed.com), the CP200 models (CP2AS-1E1 and 
CP2S-1E1 [Welch Allyn; www.welchallyn.com]), and the 
Astra300 (SDI Diagnostics; www.sdidiagnostics.com).
Safety
Members of the practice office staff trained to carry 
out spirometry should take the precautions described in 
Table 1.
Pocket spirometry for PeF
An inexpensive (US$50) electronic device with dispos-
able mouthpieces should be used.36 The first step is for 
the practice office staff to write down the predicted PEF 
using age and height from gender- and race-specific 
tables. The maneuver should be demonstrated with the 
mouthpiece (after a deep breath, coaching the patient to 
“blast” out the air). The practice office staff should attach 
a clean mouthpiece without touching it, and encourage a 
deep breath from the patient and then a 1-second blast. 
The maneuver should be repeated in cases of low or poor 
effort by the patient.
Spirometry to measure only  
Fev1 and Fev1/FvC ratio
In the US, Medicare payments for office spirometry aver-
aged about US$40 during 2009 and allowed the cost to be 
covered after 25 tests. The office staff administering spirom-
etry should dramatically demonstrate the three steps for the 
FVC maneuver: 1) “deep” inhalation, 2) “blast” out, and 
3) “keep blowing” for 6 seconds. A procedure for spirometry 
is described in Table 2.
Table 2 A procedure for spirometry
1. wash hands (staff person and patient).
2. Reassure the patient.
3. Review pre-test questionnaire.
4. Carefully enter data into the spirometer.
5. “Demonstrate” the maneuver.
6. Coach and observe body language.
7. Obtain three good maneuvers.
Table 4 Overall spirometry test session quality goals
1.   Three good FvC maneuvers (minimal start hesitation and forced 
exhalation .6 seconds)
2. Two best Fev1 
3. Quality grades 
4. eight maneuvers maximum
Abbreviations: Fev1, forced expiratory volume in the first second; FVC, forced 
vital capacity.
Table 1 Precautions to be taken during spirometry
1.   Consider spirometry contraindications, eg, hemoptysis of unknown 
origin (forced expiratory maneuver may aggravate the underlying 
condition); pneumothorax; unstable cardiovascular status (forced 
expiratory maneuver may worsen angina or cause changes in blood 
pressure), or recent myocardial infarction, or pulmonary embolus; 
thoracic, abdominal, or cerebral aneurysms (danger of rupture due  
to increased thoracic pressure); recent eye surgery; presence of an 
acute disease process that might interfere with test performance 
(nausea, vomiting); recent surgery of thorax or abdomen.
2. Ask the patient to sit in a comfortable chair (prevent falls and fatigue).
3.   wash your hands, keep hands away from your nose and mouth, and 
stay home if you have a cold or the flu.
4. wipe the spirometer with an alcohol pad.
Table 3 Common problems during office spirometry and the 
appropriate solutions
Problem Solution
Hesitant starts For the next maneuver, watch the patient 
inhale deeply, then shout “blast” before they 
start to exhale.
Poor blast effort Need more aggressive coaching (not due  
to lung disease).
enthusiastically demonstrate the FvC 
maneuver again. Yell “blast” after the deep 
inhalation and before they start to exhale.
Short maneuvers Need more aggressive coaching (not due  
to lung disease).
The patient needs to be encouraged to blow 
out longer. 
Submaximal inhalation  Dramatically demonstrate a deep breath  
and encourage maximal inhalation before  
the breath.
extra breaths Caused by nasal inhalations during 
exhalation.
Reject these maneuvers and then use nose 
clips.
Abbreviation: FvC, forced vital capacity.Clinical Interventions in Aging 2011:6 submit your manuscript | www.dovepress.com
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Common mistakes or problems encountered during office 
spirometry and the appropriate solutions can be found in 
Table 3.
Overall test session quality goals for spirometry tech-
nique should include those described in Table 4.37 Modern 
portable spirometers are programmed to apply the ATS 
  recommendations for good maneuvers, and this, together 
with certification (OSC) of well trained spirometry experts, 
will help to improve the quality of office spirometry.
Quality spirometry is best achieved by gaining rapport 
with the patient and by dramatically demonstrating the 
maneuver, closely observing the patient’s body language 
during the maneuver, repeating the demonstration as needed, 
and repeating the maneuver after a rest. Submaximal 
maneuvers will frequently cause falsely high and falsely 
low results. There can be a wide range of quality among 
staff who administer the spirometry tests; however, with a 
quality assurance program, spirometry can be performed and 
interpreted for asthma and COPD patients, and the spirometry 
results used to modify care.35 Even the elderly can perform 
good spirometry.37
Conclusion
Staging of COPD is driven by percent predicted FEV1 and 
FEV1/FVC ratio (providing the spirometry is carried out 
  correctly); however, this takes only one piece of informa-
tion into account. The authors advise that the reality of 
  concordance of symptoms (according to the validated 
St Georges Respiratory Questionnaire38 and the newly 
developed short Clinical COPD Questionnaire)39 and the 
impact of COPD on a patient’s daily living according to their 
individual needs/occupation should be taken into account. 
Although it has been suggested that PEF can be used rather 
than spirometry,33 this is not the case in primary care, as 
the gold standard in diagnosing and tracking the path of 
COPD is spirometry, FEV1, and the FEV1/FVC ratio. Using 
spirometry, primary care physicians can diagnose the pres-
ence and severity of COPD. In summary, spirometry can 
guide therapies for COPD and predict outcomes when used 
in a primary care setting.
Acknowledgments
This article was developed on the basis of the authors’ 
presentations and discussions at “Overcoming Barriers 
to COPD Identification and Management”, held in New 
York, NY, USA, 23–24 March 2009. This meeting, the 
authors’ participation, and manuscript preparation were 
supported by Boehringer Ingelheim Pharmaceuticals Inc. 
and Pfizer Inc. Medical writing assistance was provided by 
Gill  Sperrin CBiol MSB of Envision Scientific Solutions. 
The article reflects the concepts of the authors and is their sole 
  responsibility. It was not reviewed by Boehringer Ingelheim 
  Pharmaceuticals Inc. or Pfizer Inc., except to ensure medical 
and safety accuracy.
Disclosures
Tom Barnes has received consultation fees from Boehringer 
Ingelheim Pharmaceuticals Inc. and Pfizer. Len Fromer has 
received honoraria for speakers’ bureau from Boehringer 
Ingelheim Pharmaceuticals Inc. and Pfizer.
References
  1.  Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global 
strategy for the diagnosis, management and prevention of chronic 
obstructive pulmonary disease, 2009. Available from: http://www.
goldcopd.org. Accessed Jan15 2010.
  2.  Petty TL. John Hutchinson’s mysterious machine revisited. Chest. 2002; 
121 Suppl 5:S219–S223.
  3.  Chavannes N, Schermer T, Akkermans R, et al. Impact of spirometry 
on GPs’ diagnostic differentiation and decision-making. Respir Med. 
2004;98(11):1124–1130.
  4.  Dales RE, Vandemheen KL, Clinch J, et al. Spirometry in the primary 
care setting: influence on clinical diagnosis and management of airflow 
obstruction. Chest. 2005;128(4):2443–2447.
  5.  Young RP, Hopkins R, Eaton TE. Forced expiratory volume in one 
second: not just a lung function test but a marker of premature death 
from all causes. Eur Respir J. 2007;30(4):616–622.
  6.  Yawn BP, Enright PL, Lemanske RF Jr, et al. Spirometry can 
be done in family physicians’ offices and alters clinical deci-
sions in management of asthma and COPD. Chest. 2007;132(4): 
1162–1168.
  7.  Lin K, Watkins B, Johnson T, et al. Screening for chronic obstructive 
pulmonary disease using spirometry: summary of the evidence for the 
US Preventive Services Task Force. Ann Intern Med. 2008;148(7): 
535–543.
  8.  Bednarek M, Maciejewski J, Wozniak M, et al. Prevalence, severity 
and underdiagnosis of COPD in the primary care setting. Thorax. 2008; 
63(5):402–407.
  9.  Lusuardi M, de Benedetto F, Paggiaro P, et al. A randomized controlled 
trial on office spirometry in asthma and COPD in standard general 
practice: data from spirometry in asthma and COPD: a comparative 
evaluation Italian study. Chest. 2006;129(4):844–852.
  10.  Buffels J, Degryse J, Decramer M, et al. Spirometry and smoking cessa-
tion advice in general practice: a randomised clinical trial. Respir Med. 
2006;100(11):2012–2017.
  11.  Enright P. Does screening for COPD by primary care physicians have 
the potential to cause more harm than good? Chest. 2006;129(4): 
833–835.
  12.  Stratelis G, Molstad S, Jakobsson P, et al. The impact of repeated 
spirometry and smoking cessation advice on smokers with mild COPD. 
Scand J Prim Health Care. 2006;24(3):133–139.
  13.  Tashkin DP, Murray RP. Smoking cessation in chronic obstructive 
pulmonary disease. Respir Med. 2009;103(7):963–974.
  14.  Tashkin DP, Celli B, Decramer M, et al. Bronchodilator responsiveness 
in patients with COPD. Eur Respir J. 2008;31(4):742–750.
  15.  McCormack MC, Enright PL. Making the diagnosis of asthma. Respir 
Care. 2008;53(5):583–590; discussion 590–592.
  16.  Gold PM. The 2007 GOLD Guidelines: a comprehensive care 
  framework. Respir Care. 2009;54(8):1040–1049.Clinical Interventions in Aging
Publish your work in this journal
Submit your manuscript here: http://www.dovepress.com/clinical-interventions-in-aging-journal
Clinical Interventions in Aging is an international, peer-reviewed journal 
focusing on evidence-based reports on the value or lack thereof of treat-
ments intended to prevent or delay the onset of maladaptive correlates 
of aging in human beings. This journal is indexed on PubMed Central, 
MedLine, the American Chemical Society’s ‘Chemical Abstracts Ser-
vice’ (CAS), Scopus and the Elsevier Bibliographic databases. The 
manuscript management system is completely online and includes a 
very quick and fair peer-review system, which is all easy to use. Visit 
http://www.dovepress.com/testimonials.php to read real quotes from 
published authors.
Clinical Interventions in Aging 2011:6 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
Dovepress
52
Barnes and Fromer
  17.  Macintyre NR. Spirometry for the diagnosis and management of 
chronic obstructive pulmonary disease. Respir Care. 2009;54(8): 
1050–1057.
  18.  O’Donnell DE, Laveneziana P, Ora J, et al. Evaluation of acute 
  bronchodilator reversibility in patients with symptoms of GOLD stage I 
COPD. Thorax. 2009;64(3):216–223.
  19.  Goodfellow LT, Waugh JB. Tobacco treatment and prevention: what 
works and why. Respir Care. 2009;54(8):1082–1090.
  20.  Celli BR, Thomas NE, Anderson JA, et al. Effect of pharmacotherapy 
on rate of decline of lung function in chronic obstructive pulmonary 
disease: results from the TORCH study. Am J Respir Crit Care Med. 
2008;178(4):332–338.
  21.  Restrepo RD. A stepwise approach to management of stable COPD 
with inhaled pharmacotherapy: a review. Respir Care. 2009;54(8): 
1058–1081.
  22.  Tarpy SP, Celli BR. Long-term oxygen therapy. N Engl J Med. 1995; 
333(11):710–714.
  23.  Lacasse Y, Goldstein R, Lasserson TJ, et al. Pulmonary rehabilitation for 
chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 
2006;4:CD003793.
  24.  Fishman A, Martinez F, Naunheim K, et al; National Emphysema 
Treatment Trial Research Group. A randomized trial comparing lung-
volume-reduction surgery with medical therapy for severe emphysema. 
N Engl J Med. 2003;348(21):2059–2073.
  25.  Leuppi JD, Miedinger D, Chhajed PN, et al. Quality of spirometry 
in primary care for case finding of airway obstruction in smokers. 
  Respiration. 2010;79(6):469–474.
  26.  Yawn B, Mannino D, Littlejohn T, et al. Prevalence of COPD among 
symptomatic patients in a primary care setting. Curr Med Res Opin. 
2009;25(11):2671–2677.
  27.  US Preventive Services Task Force. Screening for chronic obstructive 
pulmonary disease using spirometry: US Preventive Services Task 
Force recommendation statement. Ann Intern Med. 2008;148(7): 
529–534.
  28.  COPD Foundation. Mobile spirometry unit, 2010. Available from: http://
www.copdfoundation.org/Programs/MobileSpirometryUnit/tabid/104/
language/en-US/Default.aspx. Accessed Nov 24 2010.
  29.  Nelson SB, Thomashaw BM, Enright P, et al. A tiered, economical 
approach for COPD case-finding in the general population. Am J Respir 
Crit Care Med 2010;181:A5949.
  30.  Martinez FJ, Raczek AE, Seifer FD, et al. Development and initial 
validation of a self-scored COPD Population Screener Questionnaire 
(COPD-PS). COPD. 2008;5(2):85–95.
  31.  Lamprecht B, Schirnhofer L, Tiefenbacher F, et al. Six-second spirom-
etry for detection of airway obstruction: a population-based study in 
Austria. Am J Respir Crit Care Med. 2007;176(5):460–464.
  32.  The National Lung Health Education Program (NLHEP). Strategies in 
preserving lung health and preventing COPD and associated diseases. 
Chest. 1998;113 Suppl 2:S123–S163.
  33.  White P. Spirometry and peak expiratory flow in the primary care 
management of COPD. Prim Care Respir J. 2004;13(1):5–8.
  34.  Mannino DM. COPD: epidemiology, prevalence, morbidity and mortal-
ity, and disease heterogeneity. Chest. 2002;121 Suppl 5:S121–S126.
  35.  American Association for Respiratory Care Dallas Texas. National 
Lung Health Education Program – Spirometer Review Process, 2007. 
Available from: http://www.nlhep.org/spirometer-review-process.html. 
Accessed 2010 Nov 24.
  36.  Vitalograph Ltd Buckingham England. Electronic peak flow meters, 
2009. Available from: http://www.vitalograph.co.uk/products/ 
asma-1.php. Accessed Nov 24 2010.
  37.  Enright PL. How to make sure your spirometry tests are of good quality. 
Respir Care. 2003;48(8):773–776.
  38.  Engstrom CP, Persson LO, Larsson S, et al. Reliability and validity 
of a Swedish version of the St. George’s Respiratory Questionnaire. 
Eur Respir J. 1998;11(1):61–66.
  39.  Stallberg B, Nokela M, Ehrs PO, et al. Validation of the Clinical COPD 
Questionnaire (CCQ) in primary care. Health Qual Life Outcomes. 
2009;7:26.